HUP0401868A2 - Rekombináns vakcina West Nile vírus ellen - Google Patents

Rekombináns vakcina West Nile vírus ellen

Info

Publication number
HUP0401868A2
HUP0401868A2 HU0401868A HUP0401868A HUP0401868A2 HU P0401868 A2 HUP0401868 A2 HU P0401868A2 HU 0401868 A HU0401868 A HU 0401868A HU P0401868 A HUP0401868 A HU P0401868A HU P0401868 A2 HUP0401868 A2 HU P0401868A2
Authority
HU
Hungary
Prior art keywords
expression vectors
protein
vitro
vaccines
contain
Prior art date
Application number
HU0401868A
Other languages
English (en)
Inventor
Sheens May Loosmore
Jean-Christophe Francis Audonnet
Original Assignee
Merial
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial filed Critical Merial
Publication of HUP0401868A2 publication Critical patent/HUP0401868A2/hu
Publication of HUP0401868A3 publication Critical patent/HUP0401868A3/hu
Publication of HU230122B1 publication Critical patent/HU230122B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgyát in vivo és in vitro expressziós vektorok képezik,amelyek a West Nile vírus E-fehérjét kódoló polinukleotidottartalmaznak, adott esetben együtt a prM premembránfehérjével és/vagyaz M membránfehérjével, előnyösen prM-M-E-t kódoló formában. Az invivo expressziós vektorokat élő vakcinákban alkalmazzuk. Az in vitroexpressziós vektorokat fehérjék in vitro előállítására alkalmazzák,amelyek azután alkalmazhatók alegység-vakcinákban. A találmány tárgyátképezik multivalens vakcinák is, amelyek vakcinakomponensttartalmaznak a West Nile vírus ellen és egy másik vakcinakomponenstegy másik patogén ellen. A találmány különösen lovak, kutyák, macskák,szarvasmarhák, sertések és madarak esetében alkalmazható. Ó
HU0401868A 2001-04-06 2002-04-05 Rekombináns vakcina West Nile vírus ellen HU230122B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0104737A FR2823222B1 (fr) 2001-04-06 2001-04-06 Vaccin contre le virus de la fievre du nil
FR01/04737 2001-04-06
PCT/FR2002/001200 WO2002081621A2 (fr) 2001-04-06 2002-04-05 Vaccin contre le virus de la fievre du nil

Publications (3)

Publication Number Publication Date
HUP0401868A2 true HUP0401868A2 (hu) 2004-12-28
HUP0401868A3 HUP0401868A3 (en) 2011-06-28
HU230122B1 HU230122B1 (hu) 2015-08-28

Family

ID=8862055

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0401868A HU230122B1 (hu) 2001-04-06 2002-04-05 Rekombináns vakcina West Nile vírus ellen
HUS1500047C HUS1500047I1 (hu) 2001-04-06 2015-09-18 Rekombináns vakcina West Nile vírus ellen

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS1500047C HUS1500047I1 (hu) 2001-04-06 2015-09-18 Rekombináns vakcina West Nile vírus ellen

Country Status (22)

Country Link
EP (2) EP1377660B1 (hu)
JP (1) JP4426761B2 (hu)
AU (1) AU2002307971B2 (hu)
BE (1) BE2016C021I2 (hu)
BR (1) BRPI0208896B1 (hu)
CA (1) CA2448796C (hu)
CY (2) CY1117676T1 (hu)
DK (1) DK1377660T3 (hu)
ES (2) ES2566044T3 (hu)
FR (2) FR2823222B1 (hu)
HK (2) HK1219412A1 (hu)
HU (2) HU230122B1 (hu)
IL (3) IL158204A0 (hu)
LT (1) LTC1377660I2 (hu)
LU (1) LU93048I2 (hu)
MX (1) MXPA03008998A (hu)
NL (1) NL300806I2 (hu)
PL (2) PL210306B1 (hu)
RU (1) RU2283138C2 (hu)
SI (1) SI1377660T1 (hu)
WO (1) WO2002081621A2 (hu)
ZA (1) ZA200307620B (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1337149A4 (en) 2000-10-27 2005-10-12 Irx Therapeutics Inc VACCINE IMMUNOTHERAPY FOR IMMUNE-PATIENT PATIENTS
MXPA04000680A (es) 2001-07-27 2004-04-05 Wyeth Corp Vacuna para virus west nile.
CN1726276A (zh) * 2002-12-13 2006-01-25 艾文蒂斯·帕斯图尔公司 Alvac在禽胚胎干细胞上的生产
CA2526640C (en) 2003-05-23 2014-07-15 Chiron Corporation Immunogenic reagents from west nile virus
CA2582534A1 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
AU2009287449B2 (en) 2008-08-29 2015-04-30 Boehringer Ingelheim Animal Health USA Inc. West nile virus vaccine
EP2987856B1 (en) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
BRPI1012635A2 (pt) 2009-03-27 2016-06-21 Academia Sinica "métodos e composições para imunização contra o vírus"
WO2010132867A1 (en) * 2009-05-15 2010-11-18 Irx Therapeutics, Inc. Vaccine immunotherapy
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
RU2506093C1 (ru) * 2012-12-06 2014-02-10 Государственное научное учреждение Якутский научно-исследовательский институт сельского хозяйства Российской академии сельскохозяйственных наук Способ специфической профилактики ринопневмонии, сальмонеллезного аборта и мыта лошадей ассоциированной вакциной в условиях табунного содержания
GEP20196976B (en) 2013-03-14 2019-06-10 Sloan Kettering Cancer Center Memorial Newcastle disease viruses and uses thereof
EP3441084A1 (en) 2014-02-27 2019-02-13 Viralytics Limited Oncolytic virus and immuno-stimulatory agent for combined use in the treatment of cancer

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
NZ221790A (en) 1986-09-12 1990-07-26 Genentech Inc Method for the continuous production of a heterologous protein in a eukaryotic host cell
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
EP0668355B1 (en) 1993-12-20 1999-04-07 Akzo Nobel N.V. Vaccine for the protection of horses against equine herpesvirus infection
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
FR2728794B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
JPH11504631A (ja) 1995-04-25 1999-04-27 バイカル インコーポレイテッド Ｄｎａ／脂質複合体の単一バイアル製剤
JP2002512501A (ja) 1996-07-03 2002-04-23 メリアル インコーポレイテッド 外来性ｄｎａを含む組換えイヌアデノウィルス（ｃａｖ）
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
ES2345614T3 (es) * 1997-02-28 2010-09-28 Sanofi Pasteur Biologics Co. Vacunas quimericas de flavivirus.
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
US6416763B1 (en) * 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
CZ20014392A3 (cs) 1999-06-10 2002-06-12 Merial Vakcína AND pro domácí a sportovní zvířata
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines

Also Published As

Publication number Publication date
FR16C0014I2 (fr) 2016-09-09
AU2002307971B2 (en) 2008-01-17
EP2979705A1 (fr) 2016-02-03
EP1377660A2 (fr) 2004-01-07
MXPA03008998A (es) 2004-10-15
NL300806I2 (hu) 2016-06-09
JP4426761B2 (ja) 2010-03-03
FR2823222B1 (fr) 2004-02-06
BRPI0208896B1 (pt) 2016-06-07
ZA200307620B (en) 2005-07-27
SI1377660T1 (sl) 2016-05-31
RU2283138C2 (ru) 2006-09-10
HUS1500047I1 (hu) 2017-03-28
HK1219412A1 (zh) 2017-04-07
RU2003132455A (ru) 2005-04-27
CA2448796A1 (en) 2002-10-17
CY2016018I1 (el) 2016-12-14
HUP0401868A3 (en) 2011-06-28
WO2002081621A3 (fr) 2003-02-20
IL158204A0 (en) 2004-05-12
DK1377660T3 (en) 2016-03-29
ES2767413T3 (es) 2020-06-17
LTC1377660I2 (lt) 2017-04-25
BE2016C021I2 (hu) 2021-03-23
CA2448796C (en) 2012-11-20
LU93048I2 (fr) 2016-06-27
PL207584B1 (pl) 2011-01-31
PL210306B1 (pl) 2011-12-30
ES2566044T3 (es) 2016-04-08
JP2004531521A (ja) 2004-10-14
FR2823222A1 (fr) 2002-10-11
CY1117676T1 (el) 2016-12-14
IL158204A (en) 2013-03-24
IL185263A0 (en) 2008-01-06
HU230122B1 (hu) 2015-08-28
HK1061868A1 (zh) 2004-10-08
WO2002081621A2 (fr) 2002-10-17
BR0208896A (pt) 2004-07-20
CY2016018I2 (el) 2016-12-14
EP2979705B1 (fr) 2019-10-23
EP1377660B1 (fr) 2016-01-13
FR16C0014I1 (hu) 2016-05-27
PL365210A1 (en) 2004-12-27

Similar Documents

Publication Publication Date Title
HUP0401868A2 (hu) Rekombináns vakcina West Nile vírus ellen
AR060565A1 (es) Vacuna para la gripe aviaria y metodos de uso
ECSP077888A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
UA110328C2 (en) Recombinant vaccine based on avian paramixoviruses and method for its preparation and administration
AR061930A1 (es) Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
BRPI0414893A (pt) corpos miméticos de núcleo de articulação mimética de epo humanos, composições, métodos e usos
WO2009034315A3 (en) Vaccine
BR0316346A (pt) Vacina para vìrus do nilo ocidental
AP2002002568A0 (en) Mycoplasma bovis vaccine and methods of reducing pneumonia in animals.
WO2006046017A8 (en) Vaccine and nucleic acids capable of protecting poultry against colonisation by campylobacter
DE602004028029D1 (en) Rwendung
BR112021020777A2 (pt) Vacina de subunidade do csfv
ATE552272T1 (de) Myostatin-isoform
HUP0203974A2 (hu) Javított DNS-oltóanyagok háziállatokhoz
DE602005011041D1 (de) Wachstumshormon-freisetzendes hormon verstärkt die vakzin-induzierte immunantwort
HUP0200302A2 (en) Malaria vaccine
DE602004015141D1 (de) Modifizierte ganzzell-, zellextrakt- und omv-basierte impfstoffe
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
DK1332155T3 (da) Vaccination af malkekvæg med GapC protein mod streptokokinfektion
ATE388962T1 (de) Einschlusskörper für die mündliche impfung von tieren
RU2010143584A (ru) Вакцина для защиты от haemophilus parasuis серотипа 4 у поросят
DE60126490D1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
NO20075272L (no) Humane GLP-1 "mimetibodies", sammensetninger, fremgangsmater og anvendelser
DE60236943D1 (de) Induzierte immunantwort gegen den katzen-immunschwäche-virus
Steinaa Gene editing in veterinary vaccine development: Status of the science

Legal Events

Date Code Title Description
AA1S Information on application for a supplementary protection certificate

Free format text: PRODUCT NAME: WEST NILE RECOMBINANT CANARYPOX VIRUS; REGISTRATION NO/DATE: EU/2/11/129 20110805

Spc suppl protection certif: S1500047

Filing date: 20150918

Expiry date: 20220405

FG4S Grant of supplementary protection certificate

Free format text: PRODUCT NAME: WEST NILE RECOMBINANT CANARYPOX VIRUS (VCP2017 VIENS); REGISTRATION NO/DATE: EU/2/11/129/001-004 20110810

Spc suppl protection certif: S1500047

Filing date: 20150918

Expiry date: 20220405

Extension date: 20260810